AllRock Bio is a clinical-stage biotechnology company dedicated to developing innovative therapies for cardiopulmonary and fibrotic diseases. The company's lead candidate, ROC-101, is a first-in-class, oral pan-ROCK inhibitor designed to address the significant unmet need in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). With a focus on targeting the underlying mechanisms of these life-threatening conditions, AllRock Bio aims to provide disease-modifying treatments that go beyond symptom management.